
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025

Focus on Prevention and Treatment of Cardiometabolic Disease

[10.4081/cardio.2025.86](https://doi.org/10.4081/cardio.2025.86)

Declaration of Interest Report

Stefan D. Anker (SDA), Linong Ji (LJ), Tammy Kindel (TK), Andrew J.S. Coats (AJSC), Dike Ojji (DO), Adriana Puente Barragán (APB), Peter Rossing (PR), Shelley Zieroth (SZ), Shaaf Ahmad (SA), Shariq Usman (SU), Geeta Appannah (GA), Alison L. Bailey (ALB), Ahmed Bennis (AB), Andrea Brandao (ABr), Javed Butler (JB), Melanie J. Davies (MJD), Lubomira Fabryova (LF), Yuan-Lin Guo (YLG), Hidetaka Itoh (HI), Uday M. Jadhav (UMJ), Carel W. Le Roux (CWLR), Fausto J. Pinto (FJP), Julio Rosenstock (JR), Banshi Saboo (BS), Hani Sabbour (HS), Mangesh Tiwaskar (MT), Karol E. Watson (KEW), Kwang Wei Tham (KWT), Fernando Stuardo Wyss (FSW), Walter P. Abhayaratna (WPA), William T. Abraham (WTA), Wael Al Mahmeed (WAM), Alessia Argirò (AA), John J. Atherton (JJA), Danielle Belardo (DB), Raquel Campuzano (RC), Nandini Chatterjee (NC), Marc-André Cornier (MAC), Sarah Davies (SD), Clemencia de Rueda Panadero (CRP), Anastase Dzudie (AD), Ty J. Gluckman (TJG), Muhammad Shahzeb Khan (MSK), Kamlesh Khunti (KK), Yuri Lopatin (YL), Zhiyi Ma (ZM), Okechukwu S. Ogah (OSO), Abraham Oomman (AO), Emilio Peralta (EP), Ping Li (PL), Paul Poirier (PP), Julie Redfern (JRe), Giuseppe M.C. Rosano (GMCR), Amit Saraf (AS), Sameh Shaheen (SS), Subodh Verma (SV), Stephan von Haehling (SvH), Martha Gulati (MG), Naveed Sattar (NS), Jose Luis Zamorano (JLZ), Vijay Chopra (VC), Yuhui Zhang (YZ)

SDA: grants and personal fees from Vifor and Abbott Vascular, and personal fees for consultancies, trial committee work and/or lectures from Actimed, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Brahms, Cardiac Dimensions, Cardior, Cordio, CVRx, Cytokinetics, Edwards, Farraday Pharmaceuticals, GSK, HeartKinetics, Impulse Dynamics, Occlutech, Pfizer, Regeneron, Repairon, Scirent, Sensible Medical, Servier, Vectorious, and V-Wave. Named co-inventor of two patent applications regarding MR-proANP (DE 102007010834 & DE 102007022367), but he does not benefit personally from the related issued patents.

LJ: In the past 36 months, consulting or lecture fees from Eli Lilly, Novo Nordisk, Merck, Bayer, Sanofi-Aventis, MSD, AstraZeneca, Boehringer Ingelheim, Abbott, Fosun Pharma, Innovent Biologics, Gan & Lee Pharmaceuticals, Sinocare, Sibionics.

TK: In the past 36 months, grants or contracts from American College of Surgeons, National Institute of Health; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Johnson & Johnson; support for attending

meetings and/or travel from American Society of Metabolic and Bariatric Surgery; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for Treo Foundation, American Society of Metabolic and Bariatric Surgery.

AJSC: In the past 36 months, consulting fees from Bayer, Boehringer Ingelheim, Eli Lilly, GSK, Servier, Vifor, Actimed, Cardiac Dimensions, Corvia, ESN Cleer, Faraday, Impulse Dynamics, Respicardia; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Astra Zeneca, Boehringer Ingelheim, Eli Lilly, GSK, Novartis, Novo Nordisk, Vifor, Viatrix; participation on a Data Safety Monitoring Board or Advisory Board for Impulse Dynamics.

PR: In the past 36 months, grants or contracts from Bayer, Novo Nordisk Astra Zeneca; consulting fees from Astra Zeneca, Abbott, Amgen, Boehringer Ingelheim, Bayer, Novo Nordisk Gilead, Eli Lilly; support for attending meetings and/or travel from Bayer; receipt of equipment, materials, drugs, medical writing, gifts or other services from Bayer Novo Nordisk AstraZeneca, Lexicon Pharma.

SZ: In the past 36 months, grants or contracts from AstraZeneca, Salubris Bio, Boehringer Ingelheim, Merck, Novartis, Pfizer; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Abbott, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Cytokinetics, Edwards, Eli Lilly, GSK, Medtronic, Merck, Novartis, Novo-Nordisk, Pfizer, Vifor Pharma, Not for Profit Canadian Medical and Surgical KT Group, CCS, CHFS, Charite, EOCl, Liv, Medscape, Ology, PACE- CME, Radcliffe, Reach MD, Translational Medicine Academy.

GA: In the past 36 months, leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for Malaysian Association for the Study of Obesity (MASO) (President).

ALB: In the past 36 months, consulting fees from Bristol Myers Squibb, Medtronic, for participation on Advisory Board from NovoNordisk, for P&T Committee from OptumRx; participation on a Data Safety Monitoring Board or Advisory Board for NovoNordisk; leadership or fiduciary role in other board, society, committee or advocacy group, unpaid, for the American Society of Preventive Cardiology.

ABr: In the past 36 months, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Daiichi Sankyo, Servier; support for attending meetings and/or travel from Servier, Astra Zeneca.

JB: In the past 36 months, consulting fees from Abbott, Adaptix, American Regent, Amgen, AskBio, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardiac Dimension, Cardior, CSL Vifor, CVRx, Cytokinetics, Daxor, Diastol, Edwards, Element Sciences, Faraday, Idorsia, Impulse Dynamics, Imbria, Innolife, Intellia, Inventiva, Levator, Lexicon, Eli Lilly, Mankind, Medtronic, Merck, New Amsterdam, Novartis, NovoNordisk, Pfizer, Pharmacosmos, Pharmain, Prolaio, Pulnovo, Regeneron, Renibus, Reprieve, Roche, Rycarma, Saillant,

Salamandra, Salubris, SC Pharma, SQ Innovation, Secretome, Sequanna, Transmural, TekkunLev, Tenex, Tricog, Ultronic, Vera, Zoll; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Boehringer Ingelheim-Lilly, Impulse Dynamics, Merck.

MJD: In the past 36 months, grants or contracts from AstraZeneca, Boehringer Ingelheim, Novo Nordisk; consulting fees from Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Sanofi, Eli Lilly; support for attending meetings and/or travel from Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Amgen, AstraZeneca, Biomea Fusion, Regeneron, Zealand Pharma; participation on a Data Safety Monitoring Board or Advisory Board for Amgen, AstraZeneca, Biomea Fusion, Sanofi, Zealand Pharma, Carmot/Roche, Regeneron, EktaH, AbbVie, GSK, Daewoong Pharmaceutical.

HI: In the past 36 months, consulting fees from Pfizer.

CWLR: In the past 36 months, grants or contracts from Irish Research Council, Health Research Board, Science Foundation Ireland, Anabio; consulting fees from Novo Nordisk, Eli Lilly, Johnson&Johnson, Boehringer Ingelheim, GI Dynamics, Herbalife, Altimune, Irish Life Health, Amgen, Arrowhead, Roche, AstraZeneca, Keyron, Gila Pharmaceuticals, Metsera, Nymble, AbbVie, Olympus; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novo Nordisk, Herbalife, Johnson&Johnson, Eli Lilly, Boehringer Ingelheim, Rhythm Pharmaceuticals, Currax Pharmaceuticals; support for attending meetings and/or travel from Novo Nordisk, Herbalife, Johnson&Johnson, Eli Lilly, Boehringer Ingelheim; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for Irish Society for Nutrition and Metabolism; stock or stock options for Metsera, Nymble; other financial or non-financial interests - My Best Weight (co-owner), Beyond BMI (co-owner).

FJP: In the past 36 months, consulting fees from Boehringer Ingelheim, Daichi Sankyo, Novartis, Servier, Vifor; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Boehringer Ingelheim, Daichi Sankyo, Novartis, Servier, Vifor, Zydus; participation on a Data Safety Monitoring Board or Advisory Board for Medtronic, Novartis, Servier, Vifor; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for Immediate Past-President, World Heart Federation (WHF), Past-President, European Society of Cardiology (ESC).

JR: In the past 36 months, grants or contracts from Amgen, Applied Therapeutics, AstraZeneca, Biomea Fusion, BioAge, Boehringer Ingelheim, Carmot, Corcept, Corxel, Eli Lilly, Hanmi, Merck, Novartis, Novo Nordisk, Oramed, Pfizer, Regeneron, Roche, Regor, Sanofi, Structure Therapeutics, and Terns; served in scientific advisory boards and received honorarium or consulting fees from Amgen, Applied Therapeutics, Biomea Fusion, Boehringer Ingelheim, Eccogene, Eli Lilly, Hanmi, i2O Therapeutics, Novo Nordisk, Oramed, Regeneron, Roche, Sanofi, Structure Therapeutics, and Terns; honoraria for lectures sponsored by Eli Lilly, Novo Nordisk and Sanofi; support for attending meetings and/or travel from Eli Lilly and Novo Nordisk.

HS: In the past 36 months, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events - all such honoraria were donated to patient supporting organizations in United Arab Emirates.

MT: In the past 36 months, leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for (Editor-in-chief) Journal of Association of Physicians of India.

KEW: In the past 36 months, consulting fees from Amgen, Amarin, Astra Zeneca, Eli Lilly; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Boehringer Ingelheim, Eli Lilly.

KWT: In the past 36 months, consulting fees from Novo Nordisk; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novo Nordisk, Eurodrug Laboratories BV, iNova Pharmaceuticals, DKSH, Boehringer Ingelheim, Abbott Nutrition; support for attending meetings and/or travel from Novo Nordisk; participation on a Data Safety Monitoring Board or Advisory Board for Novo Nordisk, DKSH, Boehringer Ingelheim, Abbott Nutrition; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for Singapore Association for the Study of Obesity, International Federation for the Study of Obesity and Metabolic Disorders Asia Pacific Chapter (IFSO APC) Integrated Health; receipt of equipment, materials, drugs, medical writing, gifts or other services from Novo Nordisk (medical writing).

WPA: In the past 36 months, consulting fees from Novo Nordisk, Boehringer Ingelheim, Eli Lilly; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novo Nordisk, Boehringer Ingelheim, Eli Lilly; support for attending meetings and/or travel from Novo Nordisk, Boehringer Ingelheim, Eli Lilly; participation on a Data Safety Monitoring Board or Advisory Board for Novo Nordisk, Boehringer Ingelheim, Eli Lilly.

WTA: In the past 36 months, grants or contracts from National Institutes of Health (National Heart, Lung, and Blood Institute); consulting fees from Abbott, AquaPass, Cordio, CVRx, Innoventric, Relief Cardiovascular, Sensible Medical, Vectorious, White Swell, Zoll Respiscardia; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Impulse Dynamics; patents planned, issued or pending - Applicant Ohio State Innovation Foundation, Inventors Emre Ertin and William T Abraham, Mobile Ultrawideband Radar for Monitoring Thoracic Fluid Levels and Cardio-Respiratory Function (Publication No. US2021/0290074 A1); leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for Heart Failure Collaboratory (HFC), (Co-Chair), Regulatory Policy and Implementation Science Working Group, (Co-Chair) HFC Academic Research Consortium Group, scPharmaceuticals, V-Wave, Cardiac Dimensions; stock or stock options for scPharmaceuticals, V-Wave, Cardiac Dimensions.

JJA: In the past 36 months, grants or contracts from American Regent: HEART-FID PI, Bayer: FINEARTS-HF National PI, Merck Sharp and Dome: VICTOR-HF PI, Novo Nordisk: POSEIDON PI, Novo Nordisk: HERMES PI; consulting fees from AstraZeneca Heart Failure Advisory Board,

Boehringer Ingelheim Heart Failure Advisory Board, Bristol-Myers Squibb Hypertrophic Cardiomyopathy Advisory Board, CSL Seqirus Cardiovascular Advisory Board, Eli Lilly: Heart Failure Advisory Board, Novo Nordisk Advisory Board, Roche Diagnostics: NT-proBNP Advisory Board; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Novo Nordisk; support for attending meetings and/or travel from Bayer, Bristol-Myers Squibb, Echo IQ, Novartis, Novo Nordisk, Vifor Pharma; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for Australian Government Medical Services (Advisory Committee), Australian Government MBS Review (Advisory Committee).

RC: In the past 36 months, consulting fees from Novo Nordisk; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novo Nordisk, Eli Lilly.

MAC: In the past 36 months, grants or contracts from Novartis, Amgen, Ionis, Kaneka, Cleerly; consulting fees from Astra Zeneca, Enveda, Keros, Rivus, Wave, Zyversa; participation on a Data Safety Monitoring Board or Advisory Board for Advarra, Biophytis, Eli Lilly, Novo Nordisk; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for The Obesity Society.

SD: In the past 36 months, consulting fees from Roche, Boehringer Ingelheim, Novo Nordisk; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Boehringer Ingelheim, Lilly, Novo Nordisk, AZ, Dexcom, Abbott, Menarini, Daiichi Sankyo; support for attending meetings and/or travel from Daiichi Sankyo, Menarini; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for Primary Care Diabetes and Obesity Society (Committee Member), CaReMe UK (Committee member).

TJG: In the past 36 months, consulting fees from OptumRx; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for American Society for Preventive Cardiology.

MSK: In the past 36 months, has received fees from Bayer and Novartis.

KK: In the past 36 months, grants or contracts from AstraZeneca, Boehringer Ingelheim, Lilly, MSD, Novo Nordisk, Sanofi, Servier, Oramed Pharmaceuticals, Roche, Daiichi-Sankyo, Applied Therapeutics; consulting fees from Amgen, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Lilly, Novo Nordisk, Sanofi, Servier, Pfizer, Roche, Daiichi-Sankyo, Embecta, Nestle Health Science; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Amgen, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Lilly, Novo Nordisk, Sanofi, Servier, Pfizer, Roche, Daiichi-Sankyo, Embecta, Nestle Health Science.

EP: In the past 36 months, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novo Nordisk, Astrazeneca; support for attending

meetings and/or travel from Novo Nordisk.

PP: In the past 36 months, grants or contracts from Amgen, Novo Nordisk; consulting fees from Amgen, Novo Nordisk; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Amgen, Novo Nordisk.

JRe: In the past 36 months, grants or contracts from NHMRC (Investigator Grant), NHMRC Synergy (Grant), MRFF Impact Evaluation; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for (Member) Board of World Heart Federation, (Chair) Scientific Advisory Committee, Australian Cardiovascular Alliance, (Editor) NPJ Digital Medicine.

GMCR: In the past 36 months, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Anlylam, Astra Zeneca, Bayer, Boehringer Ingelheim, Cipla, CSL Vifor, Medtronic, Servier, Viatrix.

SvH: In the past 36 months, grants or contracts from Amgen, Boehringer Ingelheim, IMI, and the German Center for Cardiovascular Research (DZHK), Pharmacosmos, AstraZeneca; consulting fees from AstraZeneca, Bayer, Besins Healthcare, Boehringer, BRAHMS, CSL Vifor, Edwards Lifesciences, MSD, Novartis, Novo Nordisk, Pharmacosmos.

MG: In the past 36 months, consulting fees from Medtronic, Edwards Lifesciences, Bayer, Amgen; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Zoll; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for Immediate Past President ASPC.

NS: In the past 36 months, grants or contracts from AstraZeneca, Boehringer Ingelheim, Novartis, Roche Diagnostics; consulting fees from AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Carmot Therapeutics, Eli Lilly, GlaxoSmithKline, Hanmi Pharmaceuticals, Menarini-Ricerche, Metsera, Novartis, Novo Nordisk, Pfizer, Roche; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Abbott Laboratories, AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Roche.

JLZ: In the past 36 months, consulting fees from Sanofi; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from MSD, Novartis, Amgen.

VC: in the past 36 months, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Pfizer, AstraZeneca, Novartis, Sun Pharma,

Boehringer, Sanofi, NovoNordisk, Mankind, Lupin, Cipla, Torrent, Dr. Reddy's.

DO, APB, SA, SU, AB, LF, YLG, UMJ, BS, FSW, WAM, AA, DB, NC, CRP, AD, YL, ZM, OSO, AO, PL, AS, SS, SV, YZ: report no conflicts of interest.

Supplement to the paper: *Anker SD et al. iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity.*
Global Cardiology 2025. <https://doi.org/10.4081/cardio.2025.86>